Skip to content
Descubridor Institucional UMAR
Inicio
Búsqueda avanzada
Explorar
Inicio
Búsqueda avanzada
Explorar
Login
Language
English
Deutsch
Español
Français
Italiano
All Fields
Title
Author
Subject
Call Number
ISBN/ISSN
Tag
Find
Advanced
Elranatamab Exposure–Safety Analysis in Relapsed or Refractory Multiple Myeloma
Elranatamab Exposure–Safety Analysis in Relapsed or Refractory Multiple Myeloma
Fuente:
Wiley Open Access
Saved in:
Bibliographic Details
Main Authors:
Pooneh Soltantabar
,
Jennifer Hibma
,
Diane Wang
,
Umberto Conte
,
Anne Hickman
,
Mohamed Elmeliegy
Format:
Artículo Open Access
Published:
Wiley
2025
Subjects:
The Journal of Clinical Pharmacology
Online Access:
Acceder al recurso
Tags:
Add Tag
No Tags, Be the first to tag this record!
Cite this
Text this
Email this
Print
Export Record
Export to RefWorks
Export to EndNoteWeb
Export to EndNote
Save to List
Permanent link
Holdings
Description
Comments
Similar Items
Staff View
Internet
https://accp1.onlinelibrary.wiley.com/doi/10.1002/jcph.70130
Similar Items
Impact of Treatment Modality and Route of Administration on Cytokine Release Syndrome in Relapsed or Refractory Multiple Myeloma: A Meta‐Analysis
by: Pooneh Soltantabar, et al.
Published: (2024)
A Novel Two‐Part Mixture Model for the Incidence and Time Course of Cytokine Release Syndrome After Elranatamab Dosing in Multiple Myeloma Patients
by: Donald Irby, et al.
Published: (2025)
Characterizing Cellular Expansion of Idecabtagene Vicleucel and Association with Clinical Efficacy and Safety in Patients with Triple‐Class‐Exposed Relapsed/Refractory Multiple Myeloma
by: Fan Wu, et al.
Published: (2025)
Limitations of Subgroup Safety Analyses for Drug–Drug Interaction Evaluation: Insights from the Talazoparib P‐gp Inhibitor Case
by: Diane Wang, et al.
Published: (2026)
Population Pharmacokinetics of Valemetostat and Exposure–Response Analyses of Efficacy and Safety in Patients with Relapsed/Refractory Peripheral T–Cell Lymphoma
by: Hiroyuki Inoue, et al.
Published: (2025)